MwanzoNVAX • SWX
add
Novavax Inc
Thamani ya kampuni katika soko
1.76B USD
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 147.14M | 66.61% |
Matumizi ya uendeshaji wa biashara | 4.31M | -92.26% |
Mapato halisi | 17.53M | 121.63% |
Kiwango cha faida halisi | 11.91 | 112.98% |
Mapato kwa kila hisa | 0.11 | 121.33% |
EBITDA | 26.06M | 123.07% |
Asilimia ya kodi ya mapato | 2.10% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 735.08M | -20.37% |
Jumla ya mali | 1.18B | -24.60% |
Jumla ya dhima | 1.30B | -40.29% |
Jumla ya hisa | -127.75M | — |
hisa zilizosalia | 162.94M | — |
Uwiano wa bei na thamani | — | — |
Faida inayotokana na mali | 4.44% | — |
Faida inayotokana mtaji | 42.77% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 17.53M | 121.63% |
Pesa kutokana na shughuli | -39.48M | 77.20% |
Pesa kutokana na uwekezaji | 20.48M | -85.78% |
Pesa kutokana na ufadhili | -6.60M | -92.99% |
Mabadiliko halisi ya pesa taslimu | -27.30M | 36.93% |
Mtiririko huru wa pesa | -2.35M | 98.13% |
Kuhusu
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1987
Makao Makuu
Tovuti
Wafanyakazi
749
